Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
2006-01-10
2006-01-10
Smith, Lynette R. F. (Department: 1645)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
C424S239100, C435S006120, C536S023100, C800S008000
Reexamination Certificate
active
06984375
ABSTRACT:
Methods for determining the effect of aClostridaltoxin on muscle are disclosed. In particular, methods for determining a potency and/or diffusion of a toxin based on a nuclear index and/or the extent of muscle atrophy are disclosed.
REFERENCES:
patent: 5158976 (1992-10-01), Rosenberg
patent: 5183462 (1993-02-01), Borodic
patent: 5298019 (1994-03-01), Borodic
patent: 5314805 (1994-05-01), Haugland et al.
patent: 5401243 (1995-03-01), Borodic
patent: 5548661 (1996-08-01), Price et al.
patent: 5696077 (1997-12-01), Johnson et al.
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5856665 (1999-01-01), Price et al.
patent: 6143306 (2000-11-01), Donovan
patent: 6235289 (2001-05-01), Aoki et al.
patent: 6306403 (2001-10-01), Donovan
patent: 6309883 (2001-10-01), Minshull et al.
patent: 6358926 (2002-03-01), Donovan
patent: 6416765 (2002-07-01), Donovan
patent: 6416959 (2002-07-01), Giuliano et al.
patent: 6429189 (2002-08-01), Borodic
patent: 6485413 (2002-11-01), Boppart et al.
patent: 6620415 (2003-09-01), Donovan
patent: 6673024 (2004-01-01), Soito et al.
patent: 2002/0137886 (2002-09-01), Lin et al.
patent: 2002/0197278 (2002-12-01), Allison
patent: 2003/0026760 (2003-02-01), Holland et al.
patent: 2003/0032069 (2003-02-01), Muraca
patent: 2004/0228881 (2004-11-01), Oliver et al.
patent: 99/03483 (1999-01-01), None
Limousin, Patricia et al, Treatment of dystonia occurring in Parkinsonian syndromes bybotulinumtoxin, Eur. Neurol. 1997, vol. 37, pp. 66-67.
Duchen, LW, Journal of the neurological sciences, Sep. 1971, vol. 14(1), p 47-74 ,electron microscopic structure of slow and fast skeletal muscle fibres after the local injection ofbotulinumtoxin (cell nucleus descriptor) (abstracts only).
Sesardic, D et al, Pharmacology and Toxicology, 1996, vol. 78, pp. 283-288.
Voytik, SL et al, Development Dynamics, vol. 198, pp. 214-224, 1993.
Ellies, M et al, J Oral Maxillofac. Surg. vol. 58, pp. 1251-1256, 2000.
Borodic et al, 1992,Botulinumand Tetanus Neurotoxins (ed BR DasGupta, Plenum Press, New Y rk)pp623-645.
Ohishi, I et al, Histopathological effect ofbotulinumC2 toxin on mouse intestines. Infection Immunity, vol. 43(1), pates 54-58, 1984.
Trachtenberg, J.T. Developemental Biology, vol. 196, pp. 193-203, 1998, Fiber Apoptosis in Developing Rat Muscles is regulated by activity, neurogulin.
Van den Bergh, P et al, Brain Research, vol. 707, pp. 206-212, 1996, Effect of muscle denervation on the expression of substance P in the ventral raphe-spinal pathway of the rat.
Borodic, Gary E et al (reference of record).
Chen et al (2002, Figure 7, p. 1442, and abstract; reference of record).
Coffield, J.A. et al, The Journal of Pharmacology and Experimental Therapeutics, vol. 289, No. 3, pp. 1509-1516, 1999.
Doggweiler, R et al, The Postate, vol. 37, pp. 44-50, 1998.
Borodic, Gary E et al,Botulinumand Tetanu Neurotoxins, Edited by B.R. DesGupta, Plenum Press, New York 1992, pp. 623-645.
Chen, Chen-Ming et al, J. Appl. Physiol., vol. 93, p. 1437-1447, Jun. 30, 2002.
Spencer, RF et al, Arch. Ophthalmol, vol. 105, Dec. 1987, pp. 1703-1711.
Paisson, EM et al, The Journal of Biological Chemistry, vol. 275(11), Mar. 17, pp. 7818-7825, 2000.
Parratte, B etal, Surgical and radiological anatomy, (Germany), May 2002, vol. 24(2), pp. 91-96.
Rokx, JT et al, Acta anatomica (Switzerland), 1987, vol. 129(4), pp. 333-336.
Ellies, Met al, European Federation of Oto-Rhino-Laryngological Societies, 1999, vol. 256(3), pp. 148-152.
Giovanoli, Pe tal, Plastic and reconstructive surgery, Aug. 200, vol. 106(2), pp. 383-392.
Hill, RR et al, Journal of neurocytology, Mar. 1991, vol. 20(3), pp. 165-182.
Hott, JS et al, Neurology, Feb. 1998, vol. 50(2), pp. 485-491.
Kranjc, BS et al, Investigative ophthalmology & visual science, Dec. 2001, vol. 42(13), pp. 3158-3164.
Lu, L et al, Plastic and reconstructive surgery, Jun. 1998, vol. 101(7), pp. 1875-1880.
Mendler, L et al, Neromuscular disorders, Dec. 1998, vol. 8(8),pp. 533-541.
Mohan, M et al, Br. J. Ophthalmol, 1999, Voo. 83, p. 1306+.
Schwab, ME et al (1976) Brain Research, Mar. 26, vol. 105(2), pp. 213-227.
Bhatia, KP et al, J. Neurol. Neurosurg. Psychiatry, 1999, vol. 67, pp. 90-93.
Witzemann, V et al, FEBS Letters, (Netherlands) May 6, 1991, vol. 282(2), pp. 259-264, Differential regulation of MyoD and myogenin mRNA levles by nerve induced muscle activity.
Ansved, T, Neurology, (United States) May 1997, vol. 48(5), pp. 1440-1442, Muscle fiber atropy in leg muscles afterbotulinumtoxin type A treatment of cervical dystonia.
Aoki, K.R.,Preclinical update on Botox®(botulinum toxin type A)—purified neurotoxin complex relative to other botulinum neurotoxin preparations,European Journal of Neurology 1999, 6 (suppl 4):S3-S10.
Barry, B.W.,Novel mechanisms and devices to enable successful transdermal drug delivery,European Journal of Pharmaceutical Sciences, 14 (2001) 101-114.
Bigalke, H., et al.,Botulinum A neurotoxin inhibits non-cholinergic synaptic transmission in mouse spinal court neurons in culture,Brain Res. 1985;360:318-24.
Bigalke, H., et la.,Tetanus toxin and botulinum A toxin inhibit release and uptake of carious transmitters, as studied with particulate preparations from rat brain and spinal cord,Naunyn Schmiedebergs Arch Pharmacol, 1981: 316-244-51.
Boyd, R.S., et al.,The insulin secreting•-cell line, HIT-15 contains SNAP-25 which is a target for botulinum neurotoxin-A,Movement Disorders, vol. 10, No. 3, 1995, pp. 376.
Garcia, A., et al.,Cosmetic denervation of the muscles of facial expression with botulinum toxin,Dermatol Surg 1996, 22: pp 39-43.
Gonnelle-Gispert, C., et al.,SNAP-25a and -25b isoforms are both expressed in insulin-secreting cells and can function in insulin secretion,Biochem. J. (1999) 339, 159-165.
Habermann, E., et al.,Tetanus toxin and botulinum A and C neurotoxins inhibit noradrenaline release from cultured mouse brain,J. of Neurochemistry, 51, 522-527 (1988).
Habermann, E.,Inhibition byb tetanus and botulinum A toxin of the release of [3H]noradrenaline and [3H]GABA from rat brain homogenate,Experientia Mar. 15, 1988:44(3):224-6.
Jankovic, J., et al.,Therapy with Botulinum Toxin,Marcel Dekker, Inc., 1994, p. 5.
Li, F., et al.,Formation of binucleated cardiac myocytes in rat heart II. Cytoskeletal organization,J. Mol Cell Cardiolo 29, 1553-1565 (1997).
Lim, D.A., et al.,Interaction between astrocytes and adult subventricular zone precursors stimulates neurogenesis,Proc. Natl. Acad. Sci. USA, vol. 96, pp 7526-7531, Jun. 1999, Neurobiology.
Luna, L.E.,Manual of histologic staining methods of the armed forces institute of pathology,3rded., 1968, Chapter 6, McGraw-Hill, pp. 72-99.
Manual of Histologic and Special Staining Technics, McGraw-Hill Book Co., The Blakiston Division, 2ndEd., (1960) Chp. 6,Stains for Connective Tissue,pp. 55-95.
Marchese-Ragona, R., et al.,Management of Parotid Sialocele with Botulinum Toxin,The Laryngoscope, Aug. 1999, 109, pp. 1344-1346.
Marjama-Lyons, et al.,Tremor-predominant Parkinson's disease, Drugs and AgingApr. 2000; 16(4): 273-278.
Naumann, M., et al.,Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions,European Journal of Neurology, 1999 6 (suppl 4): S111-S115.
Pearce, L.B., et al.,Pharmacologic characterization of botulinum toxin for basic science and medicine,Toxicon, 1997 vol. 35, No. 9, pp. 1373-1412.
Pearce, L.B., et al.,Measurement of botulinum toxin activity: evaluation of the lethality assay,Toxicology and Applied Pharmacology 128, 60-77, (1994).
Sesardic, D., et al.,Refinement and validation of an alternative bioassay for potency testing of therapeutic botulinum type A toxin,Pharmacol Toxicol 1996; 78(5): 283-8.
Sanchez-Prieto, J., et al.,Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes,Eur J. Biochem Jun. 1987; 165(3):675-681.
Schantz, E., et al.,Standardized assay for Clostridium botulinum toxins,J. Assoc of Anal Chem. 1978; 61(1) pp 96-9.
Schantz, E., et al.,Properties and use of botulinum toxin and other microbial neurotoxins in medicine,Microbiological Reviews, M
Chow Edward
Holland James M.
Allergan Inc.
Donovan Stephen
Portner Ginny Allen
Smith Lynette R. F.
LandOfFree
Nuclei density and nuclei area methods for determining... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nuclei density and nuclei area methods for determining..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nuclei density and nuclei area methods for determining... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3559849